Molecule
Tapinarof is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults, among other approved uses. It is available as cream for topical use. MedsAcross supplies Tapinarof for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VTAMA cream, 1% is an aryl hydrocarbon receptor agonist indicated for: the topical treatment of plaque psoriasis in adults. the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.
Source: US FDA prescribing information
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which VTAMA cream exerts its therapeutic actions are unknown.
Source: US FDA prescribing information
Apply a thin layer of VTAMA cream to affected areas once daily. Wash hands after application, unless VTAMA cream is for treatment of the hands. VTAMA cream is not for oral, ophthalmic, or intravaginal use.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
In plaque psoriasis, the most common adverse reactions (incidence ≥ 1%) were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza. In atopic dermatitis, the most common adverse reactions (incidence ≥ 1%) were upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.
Source: US FDA prescribing information
- Store at 20°C to 25°C (68°F to 77°F) excursions permitted between 15°C and 30°C (59°F and 86°F). - Do not freeze. - Protect from exposure to excessive heat.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Tapinarof, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Vtama 1% creamTopical | Organon | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 23 May 2022 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Tapinarof and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Tapinarof, including Vtama.
Yes. The US FDA first approved Tapinarof on 23 May 2022, according to Drugs@FDA.
No listed presentation of Tapinarof is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.